\-\ Texto\\:\\ \ \(0\)\
\-\ pathology\\:\\ \ \(22\)\
\-\ \\ \\-\\ cd20\\ positive\\ small\\ lymphoid\\ cells\\ and\\ plasmacytic\\ cells\ \(0\)\
\-\ \\ \\-\\ cd3\\ less\\ frequent\\,\\ positive\\ in\\ 1\\/3\\ of\\ lymphoid\\ cells\ \(0\)\
\-\ \\ \\-\\ cd5\\,\\ cd10\\ negative\ \(0\)\
\-\ \\ \\-\\ in\\ situ\\ hybridization\\ \\â\\€\\“\\ monoclonal\\ lambda\\ positive\ \(0\)\
\-\ low\\ grade\\ b\\-cell\\ lymphoma\\ malt\\ type\\ with\\ plasmacytic\\ differentiation\ \(0\)\
\-\ low\\ grade\\ b\\-cell\\ lymphoma\\ malt\\ type\\ with\\ plasmacytic\\ differentiation\ \(0\)\
\-\ radiation\\ to\\ eye\\ and\\ orbit\ \(0\)\
\-\ persistence\\ of\\ subretinal\\ deposits\ \(0\)\
\-\ body\\ and\\ head\\ mri\\ unremarkable\ \(0\)\
\-\ lp\\ normal\ \(0\)\
\-\ vitrectomy\\:\\ scant\\ cells\\ consistent\\ with\\ chronic\\ inflammation\\.\\ \\ no\\ cytologic\\ atypia\\ or\\ monoclonal\\ b\\ cell\\ population\ \(0\)\
\-\ no\\ definite\\ response\\ to\\ systemic\\ steroids\ \(0\)\
\-\ variable\\ visual\\ acuity\\ 20\\/20\\-20\\/40\ \(0\)\
\-\ 94\\ weeks\ \(1\)\
\-\ increasing\\ subretinal\\ fluid\ \(0\)\
\-\ is\\ the\\ choroid\\ a\\ primary\\ site\\ for\\ involvement\\ with\\ lymphoproliferative\\ neoplasms\\?\ \(0\)\
\-\ what\\ is\\ the\\ spectrum\\ of\\ lymphoproliferative\\ neoplasms\\ occurring\\ at\\ that\\ site\\?\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plasmacytic\\:\\ 0\\.21157244217519597\ \(0\)\
\-\ subretinal\\:\\ 0\\.14104829478346398\ \(0\)\
\-\ malt\\:\\ 0\\.11886758500554573\ \(0\)\
\-\ lymphoproliferative\\:\\ 0\\.11529728818451837\ \(0\)\
\-\ cells\\:\\ 0\\.10964629421279992\ \(0\)\
\-\ monoclonal\\:\\ 0\\.10589270154608446\ \(0\)\
\-\ lymphoid\\:\\ 0\\.09668687522762746\ \(0\)\
\-\ b\\-cell\\:\\ 0\\.08510417380000028\ \(0\)\
\-\ differentiation\\:\\ 0\\.07284541675080293\ \(0\)\
\-\ hybridization\\:\\ 0\\.07052414739173199\ \(0\)\
\-\ 20\\/20\\-20\\/40\\:\\ 0\\.07052414739173199\ \(0\)\
\-\ neoplasms\\:\\ 0\\.06959376488499064\ \(0\)\
\-\ positive\\:\\ 0\\.0665492541668188\ \(0\)\
\-\ cd3\\:\\ 0\\.06173524908238711\ \(0\)\
\-\ cd5\\:\\ 0\\.059433792502772864\ \(0\)\
\-\ vitrectomy\\:\\ 0\\.059433792502772864\ \(0\)\
\-\ \\-\\:\\ 0\\.05861531067866763\ \(0\)\
\-\ site\\:\\ 0\\.057784187790235246\ \(0\)\
\-\ cd10\\:\\ 0\\.057648644092259185\ \(0\)\
\-\ lambda\\:\\ 0\\.05619007163790755\ \(0\)\
\-\ cd20\\:\\ 0\\.05495686619928948\ \(0\)\
\-\ cytologic\\:\\ 0\\.05495686619928948\ \(0\)\
\-\ atypia\\:\\ 0\\.0538886150582933\ \(0\)\
\-\ \\?\\:\\ 0\\.05335807200999211\ \(0\)\
\-\ grade\\:\\ 0\\.05207738868721552\ \(0\)\
\-\ scant\\:\\ 0\\.05134098520934502\ \(0\)\
\-\ 94\\:\\ 0\\.048859745782914306\ \(0\)\
\-\ lp\\:\\ 0\\.04785844063928226\ \(0\)\
\-\ type\\:\\ 0\\.04608998765355057\ \(0\)\
\-\ persistence\\:\\ 0\\.04544019366429879\ \(0\)\
\-\ 1\\/3\\:\\ 0\\.04445937508756013\ \(0\)\
\-\ situ\\:\\ 0\\.04445937508756013\ \(0\)\
\-\ deposits\\:\\ 0\\.04415745246369735\ \(0\)\
\-\ acuity\\:\\ 0\\.04305224975585082\ \(0\)\
\-\ spectrum\\:\\ 0\\.03955453930446886\ \(0\)\
\-\ lymphoma\\:\\ 0\\.039075178150231774\ \(0\)\
\-\ occurring\\:\\ 0\\.03817973724905559\ \(0\)\
\-\ low\\:\\ 0\\.038018688845862396\ \(0\)\
\-\ definite\\:\\ 0\\.03700690945552058\ \(0\)\
\-\ variable\\:\\ 0\\.036422708375401465\ \(0\)\
\-\ what\\:\\ 0\\.03609162664609863\ \(0\)\
\-\ population\\:\\ 0\\.035670476778215256\ \(0\)\
\-\ choroid\\:\\ 0\\.03488936902170392\ \(0\)\
\-\ orbit\\:\\ 0\\.03443727133959719\ \(0\)\
\-\ response\\:\\ 0\\.034263351446505934\ \(0\)\
\-\ frequent\\:\\ 0\\.03417778913357196\ \(0\)\
\-\ systemic\\:\\ 0\\.03270504484203326\ \(0\)\
\-\ b\\:\\ 0\\.03222421344947562\ \(0\)\
\-\ steroids\\:\\ 0\\.032157823026958056\ \(0\)\
\-\ visual\\:\\ 0\\.03099100801085755\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.03076564099512398\ \(0\)\
\-\ inflammation\\:\\ 0\\.029069878989395306\ \(0\)\
\-\ eye\\:\\ 0\\.02867527845689529\ \(0\)\
\-\ increasing\\:\\ 0\\.028018499559397687\ \(0\)\
\-\ pathology\\:\\ 0\\.027979187440978256\ \(0\)\
\-\ involvement\\:\\ 0\\.025055509253022534\ \(0\)\
\-\ less\\:\\ 0\\.02315152003458146\ \(0\)\
\-\ unremarkable\\:\\ 0\\.022632531349456485\ \(0\)\
\-\ radiation\\:\\ 0\\.02243400999649869\ \(0\)\
\-\ body\\:\\ 0\\.022202109701512675\ \(0\)\
\-\ negative\\:\\ 0\\.020416961290998993\ \(0\)\
\-\ primary\\:\\ 0\\.02025107410316557\ \(0\)\
\-\ fluid\\:\\ 0\\.019429112836830825\ \(0\)\
\-\ weeks\\:\\ 0\\.019402222055209188\ \(0\)\
\-\ head\\:\\ 0\\.01938881048459117\ \(0\)\
\-\ chronic\\:\\ 0\\.019255917063256\ \(0\)\
\-\ cell\\:\\ 0\\.018465925692651892\ \(0\)\
\-\ \\:\\:\\ 0\\.018084397055850642\ \(0\)\
\-\ consistent\\:\\ 0\\.016762386150649625\ \(0\)\
\-\ small\\:\\ 0\\.01574860227504895\ \(0\)\
\-\ mri\\:\\ 0\\.01570620683931696\ \(0\)\
\-\ no\\:\\ 0\\.013767106411260832\ \(0\)\
\-\ that\\:\\ 0\\.011807845828470586\ \(0\)\
\-\ normal\\:\\ 0\\.010716899636792808\ \(0\)\
\-\ at\\:\\ 0\\.009262105222653064\ \(0\)\
\-\ is\\:\\ 0\\.00899665245415561\ \(0\)\
\-\ or\\:\\ 0\\.00801218199170966\ \(0\)\
\-\ to\\:\\ 0\\.00683308973508778\ \(0\)\
\-\ in\\:\\ 0\\.006742355682244079\ \(0\)\
\-\ for\\:\\ 0\\.005832865189141721\ \(0\)\
\-\ \\,\\:\\ 0\\.004331361048276599\ \(0\)\
\-\ and\\:\\ 0\\.004320216137573243\ \(0\)\
\-\ with\\:\\ 0\\.0037441336348764715\ \(0\)\
\-\ a\\:\\ 0\\.0031727984145488103\ \(0\)\
\-\ of\\:\\ 0\\.0027960912191517225\ \(0\)\
\-\ the\\:\\ 0\\.002211988555258013\ \(0\)\
\-\ \\.\\:\\ 0\\.0002839962887787702\ \(0\)\
